Choose Site

Press Release

Morgan Lewis Advises Amneal Pharmaceuticals in Acquisition of AvKARE

December 10, 2019

PRINCETON, December 10, 2019: Morgan Lewis represented Amneal Pharmaceuticals Inc. in its agreement to acquire a 65.1% majority interest in federal healthcare company AvKARE and its related affiliate doing business as R&S Northeast (collectively, “AvKARE”). The transaction has a value of $340 million.

Amneal is a fully integrated pharmaceutical company focused on the development, manufacture, and distribution of generic and specialty drug products. AvKARE is one of the largest private-label providers of generic pharmaceuticals in the US federal agency sector, primarily focused on serving the Department of Defense and the Department of Veterans Affairs.

Partner Steve Cohen and of counsel Veronica DiCamillo led the Morgan Lewis M&A team advising Amneal with partner Matthew Schernecke leading the corporate finance team and partners Stephen Ruscus and Rebecca Dandeker providing government contracting and regulatory support.

For more, read Amneal’s announcement.